BR112015031903A8 - composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto - Google Patents

composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto Download PDF

Info

Publication number
BR112015031903A8
BR112015031903A8 BR112015031903A BR112015031903A BR112015031903A8 BR 112015031903 A8 BR112015031903 A8 BR 112015031903A8 BR 112015031903 A BR112015031903 A BR 112015031903A BR 112015031903 A BR112015031903 A BR 112015031903A BR 112015031903 A8 BR112015031903 A8 BR 112015031903A8
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
compounds
Prior art date
Application number
BR112015031903A
Other languages
English (en)
Other versions
BR112015031903A2 (pt
Inventor
Chow Maneval Edna
H Hager Jeffrey
Kahraman Mehmet
D Smith Nicholas
P Govek Steven
Original Assignee
Seragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52105249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015031903(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seragon Pharmaceuticals Inc filed Critical Seragon Pharmaceuticals Inc
Publication of BR112015031903A2 publication Critical patent/BR112015031903A2/pt
Publication of BR112015031903A8 publication Critical patent/BR112015031903A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

resumo “composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto” a presente invenção se refere aos compostos que são moduladores do receptor de estrogênio. a presente invenção também se refere às composições e medicamentos farmacêuticos que incluem os compostos descritos no presente, bem como aos métodos de utilização de tais moduladores do receptor de estrogênio, isoladamente e em combinação com outros compostos, para o tratamento de doenças ou condições que são mediadas ou dependentes dos receptores de estrogênio.
BR112015031903A 2013-06-19 2014-06-18 composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto BR112015031903A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361836901P 2013-06-19 2013-06-19
US201461952430P 2014-03-13 2014-03-13
PCT/US2014/043040 WO2014205138A1 (en) 2013-06-19 2014-06-18 Estrogen receptor modulator and uses thereof

Publications (2)

Publication Number Publication Date
BR112015031903A2 BR112015031903A2 (pt) 2017-07-25
BR112015031903A8 true BR112015031903A8 (pt) 2019-12-31

Family

ID=52105249

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015031903A BR112015031903A8 (pt) 2013-06-19 2014-06-18 composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto

Country Status (20)

Country Link
US (2) US9873684B2 (pt)
EP (1) EP3010501B1 (pt)
JP (2) JP6576916B2 (pt)
KR (1) KR20160021277A (pt)
CN (1) CN105324115B (pt)
AU (1) AU2014281511A1 (pt)
BR (1) BR112015031903A8 (pt)
CA (1) CA2912853A1 (pt)
CL (1) CL2015003456A1 (pt)
CR (1) CR20150664A (pt)
EA (1) EA031077B1 (pt)
HK (1) HK1214532A1 (pt)
IL (1) IL242611B (pt)
MX (1) MX2015017655A (pt)
PE (1) PE20160157A1 (pt)
PH (1) PH12015502621A1 (pt)
SG (1) SG11201509508YA (pt)
TW (1) TW201501710A (pt)
UA (1) UA117249C2 (pt)
WO (1) WO2014205138A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061345A2 (en) 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
SG11201509508YA (en) * 2013-06-19 2015-12-30 Seragon Pharmaceuticals Inc Estrogen receptor modulator and uses thereof
EP2862880A1 (en) 2013-10-16 2015-04-22 Solvay Acetow GmbH Acylation process
CA2941161A1 (en) 2014-03-13 2015-09-17 F.Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
CN106572990A (zh) * 2014-03-13 2017-04-19 豪夫迈·罗氏有限公司 含有雌激素受体调节剂的治疗性组合产品
KR102363174B1 (ko) 2014-03-13 2022-02-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 B형 간염 코어 단백질 알로스테릭 조정제
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
JP2017538727A (ja) * 2014-12-18 2017-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌の治療に有用な２，３−ジフェニルクロメンの誘導体
KR20230113416A (ko) 2014-12-18 2023-07-28 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체조절제 및 이의 용도
JP6325760B1 (ja) 2015-05-29 2018-05-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 四置換アルケン化合物及びその使用
EP3331906A1 (en) 2015-08-06 2018-06-13 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
TW201720802A (zh) 2015-09-15 2017-06-16 艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
EP3912680A1 (en) 2015-10-01 2021-11-24 Olema Pharmaceuticals, Inc. Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
HRP20220640T1 (hr) 2015-10-27 2022-07-08 Sun Pharma Advanced Research Company Limited Novi heterociklični antiestrogeni
US20170166551A1 (en) 2015-12-09 2017-06-15 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulator compounds
US10125135B2 (en) 2016-04-20 2018-11-13 Astrazeneca Ab Chemical compounds
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
WO2018005860A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
TW201815789A (zh) 2016-07-25 2018-05-01 瑞典商阿斯特捷利康公司 化合物
CN109937201A (zh) 2016-09-15 2019-06-25 组装生物科学股份有限公司 乙型肝炎核心蛋白调节剂
JP2020011901A (ja) * 2016-10-20 2020-01-23 協和キリン株式会社 ピロリジン化合物の製造方法
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
RS59445B1 (sr) 2016-10-24 2019-11-29 Astrazeneca Ab Derivat 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izohinolina koristan u tretmanu raka
JP2019532999A (ja) * 2016-11-04 2019-11-14 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性乳がんの治療
AU2017363699B2 (en) 2016-11-28 2021-02-18 Eisai R&D Management Co., Ltd. Salts of indazole derivative and crystals thereof
WO2018108954A1 (en) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol
KR102576011B1 (ko) 2017-01-06 2023-09-06 쥐원 쎄라퓨틱스, 인크. 암의 치료를 위한 조합 요법
JP6951451B2 (ja) 2017-01-30 2021-10-20 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ エストロゲン受容体モジュレーター
CN111386263A (zh) 2017-02-08 2020-07-07 达纳-法伯癌症研究所有限公司 调节嵌合抗原受体
AU2018217809A1 (en) 2017-02-10 2019-08-22 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
AU2018227811A1 (en) 2017-03-02 2019-09-19 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
JP7179751B2 (ja) 2017-03-13 2022-11-29 アッセンブリー バイオサイエンシズ，インコーポレイテッド Ｂ型肝炎コアタンパク質モジュレーターを作製する方法
EP4455146A2 (en) 2017-06-29 2024-10-30 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
AR123115A1 (es) 2017-10-18 2022-11-02 Novartis Ag Composiciones y métodos para la degradación selectiva de proteínas
WO2019097426A1 (en) 2017-11-16 2019-05-23 Novartis Ag Pharmaceutical combination comprising lsz102 and ribociclib
US10695333B2 (en) 2017-12-01 2020-06-30 Novartis Ag Pharmaceutical combination comprising LSZ102 and alpelisib
WO2019192533A1 (zh) * 2018-04-04 2019-10-10 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
TWI846704B (zh) 2018-06-21 2024-07-01 瑞士商赫孚孟拉羅股份公司 3-((1r,3r)-1-(2,6-二氟-4-((1-(3-氟丙基)氮雜環丁-3-基)胺基)苯基)-3-甲基-1,3,4,9-四氫-2h-吡啶并[3,4-b]吲哚-2-基)-2,2-二氟丙-1-醇之固體形式及用於製備包含經取代苯基或吡啶基部分之稠合三環化合物之製程，包括其使用方法
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
WO2021014386A1 (en) 2019-07-22 2021-01-28 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader
BR112022011827A2 (pt) 2019-12-20 2022-08-30 C4 Therapeutics Inc Composto, composição farmacêutica, uso de um composto, métodos para tratamento ou profilaxia de câncer e para tratar um paciente com um distúrbio mediado por receptor do fator de crescimento epidérmico, e, invenção
CA3165309A1 (en) 2020-03-05 2021-09-10 Christopher G. Nasveschuk Compounds for targeted degradation of brd9
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024097989A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein degraders
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors
CN115872996B (zh) * 2023-02-21 2023-05-05 山东绿叶制药有限公司 一种雌激素受体降解剂化合物及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US5011692A (en) 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) * 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6262270B1 (en) 1998-08-14 2001-07-17 Schering Corporation Enantioselective synthesis
CA2393045A1 (en) 1999-12-07 2001-06-14 Sumitomo Chemical Co., Ltd. Mutant er.alpha. and test systems for transactivation
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
ATE286894T1 (de) 2001-01-24 2005-01-15 Chiesi Farma Spa 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
WO2004091488A2 (en) * 2003-04-14 2004-10-28 Merck & Co., Inc. Estrogen receptor modulators
CN102939287B (zh) * 2010-06-10 2016-01-27 塞拉根制药公司 雌激素受体调节剂及其用途
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
EP4234034A3 (en) * 2011-10-14 2023-09-20 F. Hoffmann-La Roche AG Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
CN104114551B (zh) * 2011-12-14 2017-01-18 塞拉根制药公司 氟化雌激素受体调节剂及其用途
SG11201405918XA (en) 2012-03-20 2014-10-30 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
EP2855479B1 (en) * 2012-04-05 2016-03-30 Boehringer Ingelheim International GmbH 1,8-naphthyridin-2(1h)-one derivatives as cytomegalovirus inhibitors
CN105121413B (zh) 2013-03-14 2018-09-14 赛拉根医药股份有限公司 多环雌激素受体调节剂及其用途
SG11201509508YA (en) * 2013-06-19 2015-12-30 Seragon Pharmaceuticals Inc Estrogen receptor modulator and uses thereof
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
EP3089747A1 (en) 2013-12-06 2016-11-09 F. Hoffmann-La Roche AG Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
CA2941161A1 (en) 2014-03-13 2015-09-17 F.Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
CN106572990A (zh) 2014-03-13 2017-04-19 豪夫迈·罗氏有限公司 含有雌激素受体调节剂的治疗性组合产品
US9493945B2 (en) 2014-07-18 2016-11-15 Williams Scotsman, Inc. Wall panel connecting system for modular building units
JP2017538727A (ja) 2014-12-18 2017-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌の治療に有用な２，３−ジフェニルクロメンの誘導体
WO2016097071A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof

Also Published As

Publication number Publication date
EP3010501A4 (en) 2017-02-01
KR20160021277A (ko) 2016-02-24
EA031077B1 (ru) 2018-11-30
US20160090378A1 (en) 2016-03-31
JP2016523253A (ja) 2016-08-08
WO2014205138A1 (en) 2014-12-24
JP6576916B2 (ja) 2019-09-18
PE20160157A1 (es) 2016-03-18
AU2014281511A1 (en) 2015-12-03
CL2015003456A1 (es) 2016-07-29
CR20150664A (es) 2016-01-29
US10227334B2 (en) 2019-03-12
UA117249C2 (uk) 2018-07-10
US20170275273A1 (en) 2017-09-28
EP3010501B1 (en) 2021-11-03
JP2019142871A (ja) 2019-08-29
US9873684B2 (en) 2018-01-23
HK1214532A1 (zh) 2016-07-29
TW201501710A (zh) 2015-01-16
IL242611B (en) 2018-10-31
EP3010501A1 (en) 2016-04-27
CN105324115B (zh) 2019-01-04
CN105324115A (zh) 2016-02-10
PH12015502621A1 (en) 2016-03-07
EA201592214A1 (ru) 2016-06-30
BR112015031903A2 (pt) 2017-07-25
SG11201509508YA (en) 2015-12-30
CA2912853A1 (en) 2014-12-24
MX2015017655A (es) 2016-04-15

Similar Documents

Publication Publication Date Title
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
BR112015022566A2 (pt) composto e composição farmacêutica
BR112015030595A2 (pt) moduladores de receptor de estrogênio de azetidina e usos dos mesmos
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
BR112013006395A2 (pt) moduladores do receptor de estrogênio e seus usos.
BR112012007102A2 (pt) compostos policíclicos como antagonistas de receptores do ácido lisofosfatpidico
BR112014014124A2 (pt) Moduladores do receptor de estrogênio fluorados e usos dos mesmos
EA201270815A1 (ru) Модуляторы рецепторов эстрогена и их применение
BR112014026952A2 (pt) derivados de aminopirimidina pirazol como moduladores lrrk2
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
BR112015018882A2 (pt) derivados de benzotiofeno e composições dos mesmos como degradadores de receptor de estrogênio seletivo
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
BR112015030387A8 (pt) compostos de pirazol moduladores de fshr, seu processo de fabricação, composição farmacêutica que os compreende, bem como uso dos mesmos
CO7160008A2 (es) Derivados de estra- 1,3,5(10),16- tetraeno 3-sustituidos, métodos para su preparación, prepara-ciones farmaceúticas que los contienen, así como su uso para la preparación de medicamentos
BR112014011341A2 (pt) composições farmacèuticas e métodos de uso de derivados de 4-pregenen-11beta-17-21-triol-3,20-diona
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
EA201501163A1 (ru) Модуляторы рецептора cxcr7
BR112017013998A2 (pt) novos derivados de benzimidazol como agentes anti-histamínicos
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112013025682A2 (pt) Compostos, composição farmacêutica, uso de um composto, combinação e dispositivo
BR112015032161A2 (pt) método para prevenir e/ou tratar encefalopatia traumática crônica, composição farmacêutica e uso de antagonista do receptor da substância p

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]